Independent Financial Group LLC Makes New $782,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Independent Financial Group LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 1,012 shares of the biopharmaceutical company’s stock, valued at approximately $782,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Prosperity Consulting Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 5.9% during the first quarter. Prosperity Consulting Group LLC now owns 360 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 20 shares during the period. Aware Super Pty Ltd as trustee of Aware Super bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $2,938,000. Wealthfront Advisers LLC lifted its position in Regeneron Pharmaceuticals by 2.5% during the 1st quarter. Wealthfront Advisers LLC now owns 8,344 shares of the biopharmaceutical company’s stock valued at $6,447,000 after purchasing an additional 202 shares during the period. Geneos Wealth Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 15 shares during the last quarter. Finally, Sanctuary Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Sanctuary Advisors LLC now owns 40,631 shares of the biopharmaceutical company’s stock worth $31,393,000 after buying an additional 1,649 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of several analyst reports. Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Finally, Barclays decreased their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $787.88.

Regeneron Pharmaceuticals Price Performance

REGN opened at $675.19 on Wednesday. The stock has a market cap of $71.38 billion, a P/E ratio of 16.45, a P/E/G ratio of 1.49 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $639.22 and a 200 day simple moving average of $716.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the firm earned $8.22 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued analyst confidence in the company’s longer-term outlook.
• Neutral Sentiment: Regeneron said it completed a mid-stage study for REGN7544 in POTS, which could be relevant for its pipeline, but the market impact is unclear from the update alone.
• Negative Sentiment: Multiple law firms announced or reminded investors about a pending class action lawsuit against Regeneron related to disclosures around a Phase 3 melanoma study failure, reinforcing legal and reputational risk for the stock.
• Negative Sentiment: The lawsuit filings and deadline reminders suggest the company faces ongoing litigation risk and potential distraction as investors focus on trial disclosure concerns rather than near-term fundamentals.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.